Abstract
Thiopurines are effective in maintaining remission in chronic inflammatory bowel diseases, but incomplete response or side effects are common during standard-dose treatment. In this article thiopurine metabolism and pharmacogenetic aspects are summarized showing their benefits in improving therapy in chronic inflammatory bowel disease. An increasing body of evidence suggests that a large part of the observed non-pancreatic side effects and poor responses can be solved by tailoring thiopurine therapy using measurement of thiopurine methyltransferase and metabolites and by using a combination therapy with low-dose thiopurines and allopurinol.
Bidragets oversatte titel | Optimized thiopurine treatment in chronic inflammatory bowel disease. |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 176 |
Udgave nummer | 22 |
Sider (fra-til) | 2-5 |
Antal sider | 4 |
ISSN | 0041-5782 |
Status | Udgivet - 2014 |